WEE1 and neoplasm: Mean peak total AZD1775 plasma concentration over 100 ng·mL−1 with single 200 mg or 400 mg doseMean unbound AZD1775 tumour concentration of 85 ng·g−1 at 2–24 h exceeding the in vitro IC50 (40 ng·mL−1) for WEE1 inhibitionConfirmation of target effects including elevated γH2AX, pH3 and cleaved caspase‐3